Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
O76093
UPID:
FGF18_HUMAN
Alternative names:
zFGF5
Alternative UPACC:
O76093; D3DQL7; Q6UWF1
Background:
Fibroblast growth factor 18 (FGF18), also known as zFGF5, is a pivotal protein in cellular processes, including cell proliferation, differentiation, and migration. Its role is crucial for normal bone development and ossification, as well as stimulating hepatic and intestinal proliferation.
Therapeutic significance:
Understanding the role of Fibroblast growth factor 18 could open doors to potential therapeutic strategies, particularly in disorders related to abnormal cell growth, bone development anomalies, and digestive system diseases.